These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 9815721

  • 1. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S.
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
    Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson BL, Plasse T.
    Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW.
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB.
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [Abstract] [Full Text] [Related]

  • 8. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL, Stadler WM, Vogelzang NJ.
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [Abstract] [Full Text] [Related]

  • 9. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH.
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [Abstract] [Full Text] [Related]

  • 10. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Jan; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M.
    J Immunother; 2008 Jan; 31(6):569-76. PubMed ID: 18528297
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R.
    Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.
    J Clin Oncol; 2003 Jul 01; 21(13):2564-73. PubMed ID: 12829677
    [Abstract] [Full Text] [Related]

  • 17. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.
    J Clin Oncol; 2008 Apr 20; 26(12):2034-9. PubMed ID: 18347008
    [Abstract] [Full Text] [Related]

  • 19. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
    Hank JA, Albertini M, Wesly OH, Schiller JH, Borchert A, Moore K, Bechhofer R, Storer B, Gan J, Gambacorti C.
    Clin Cancer Res; 1995 May 20; 1(5):481-91. PubMed ID: 9816007
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.
    Clin Cancer Res; 1995 Oct 20; 1(10):1145-52. PubMed ID: 9815906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.